SG11201701960XA - Compounds and compositions for modulating egfr mutant kinase activities - Google Patents
Compounds and compositions for modulating egfr mutant kinase activitiesInfo
- Publication number
- SG11201701960XA SG11201701960XA SG11201701960XA SG11201701960XA SG11201701960XA SG 11201701960X A SG11201701960X A SG 11201701960XA SG 11201701960X A SG11201701960X A SG 11201701960XA SG 11201701960X A SG11201701960X A SG 11201701960XA SG 11201701960X A SG11201701960X A SG 11201701960XA
- Authority
- SG
- Singapore
- Prior art keywords
- compositions
- compounds
- kinase activities
- egfr mutant
- mutant kinase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462063394P | 2014-10-13 | 2014-10-13 | |
PCT/KR2015/010784 WO2016060443A2 (fr) | 2014-10-13 | 2015-10-13 | Composés et compositions destinés à moduler les activités kinase de l'egfr mutant |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201701960XA true SG11201701960XA (en) | 2017-04-27 |
Family
ID=55654993
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201701960XA SG11201701960XA (en) | 2014-10-13 | 2015-10-13 | Compounds and compositions for modulating egfr mutant kinase activities |
Country Status (25)
Country | Link |
---|---|
US (1) | US9593098B2 (fr) |
EP (3) | EP3929190A1 (fr) |
JP (3) | JP6524221B2 (fr) |
KR (5) | KR102073854B1 (fr) |
CN (2) | CN106795144B (fr) |
AU (1) | AU2015331166B2 (fr) |
BR (1) | BR112017007769B1 (fr) |
CA (1) | CA2962914C (fr) |
CY (2) | CY1122737T1 (fr) |
DK (2) | DK3207035T3 (fr) |
ES (2) | ES2770058T3 (fr) |
HR (2) | HRP20200201T1 (fr) |
HU (2) | HUE048006T2 (fr) |
LT (2) | LT3604294T (fr) |
MX (3) | MX2020002168A (fr) |
NZ (1) | NZ730012A (fr) |
PH (1) | PH12017500488A1 (fr) |
PL (2) | PL3207035T3 (fr) |
PT (2) | PT3207035T (fr) |
RS (2) | RS61865B1 (fr) |
RU (2) | RU2727700C2 (fr) |
SG (1) | SG11201701960XA (fr) |
SI (2) | SI3207035T1 (fr) |
TW (2) | TWI730331B (fr) |
WO (1) | WO2016060443A2 (fr) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUE048006T2 (hu) * | 2014-10-13 | 2020-05-28 | Yuhan Corp | Vegyületek és készítmények EGFR mutáns kináz aktivitás modulására |
JP2018527362A (ja) | 2015-09-11 | 2018-09-20 | サンシャイン・レイク・ファーマ・カンパニー・リミテッドSunshine Lake Pharma Co.,Ltd. | 置換されたヘテロアリール化合物および使用方法 |
US10435388B2 (en) | 2016-01-07 | 2019-10-08 | Cs Pharmatech Limited | Selective inhibitors of clinically important mutants of the EGFR tyrosine kinase |
SG11201809751XA (en) * | 2016-05-26 | 2018-12-28 | Zeno Royalties & Milestones Llc | Egfr inhibitor compounds |
KR102030886B1 (ko) * | 2016-09-23 | 2019-10-10 | 재단법인 대구경북첨단의료산업진흥재단 | 신규한 이미다졸일 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물 |
AR111469A1 (es) * | 2017-04-21 | 2019-07-17 | Yuhan Corp | Sal de un compuesto del derivado de aminopiridina, una forma cristalina de la misma, y un proceso para preparar la misma |
MY199042A (en) * | 2017-06-13 | 2023-10-11 | Beijing Adamadle Biotechnology Llc | Aminopyrimidine compound, preparation method therefor and use thereof |
UA125317C2 (uk) * | 2017-07-28 | 2022-02-16 | Юхан Корпорейшн | Удосконалений спосіб отримання похідних амінопіримідину |
HRP20220848T1 (hr) * | 2017-07-28 | 2022-10-14 | Yuhan Corporation | Intermedijeri korisni za sintezu derivata aminopirimidina, postupak za njihovu proizvodnju, i postupak za proizvodnju derivata aminopirimidina koji ih koriste |
CA3070070A1 (fr) * | 2017-07-28 | 2019-01-31 | Yuhan Corporation | Intermediaires utiles pour la synthese d'un inhibiteur selectif vis-a-vis de la proteine kinase et leurs procedes de preparation |
CN111518082B (zh) * | 2017-08-30 | 2021-09-17 | 深圳市塔吉瑞生物医药有限公司 | 一种氨基嘧啶类化合物及包含该化合物的组合物及其用途 |
CN108047207A (zh) * | 2018-01-30 | 2018-05-18 | 天津大学 | N-[5-(嘧啶-2-氨基)-2,4-二取代苯基]-2-氟代丙烯酰胺氘代物及应用 |
CN108017633A (zh) * | 2018-01-30 | 2018-05-11 | 天津大学 | N-[5-(嘧啶-2-氨基)-2,4-二取代苯基]-2-氟代丙烯酰胺衍生物及应用 |
KR20200043618A (ko) * | 2018-10-18 | 2020-04-28 | 주식회사유한양행 | 아미노피리미딘 유도체 또는 이의 염을 포함하는 경구투여용 약학 조성물 |
WO2020125391A1 (fr) * | 2018-12-21 | 2020-06-25 | 深圳市塔吉瑞生物医药有限公司 | Composé aminopyrimidine utilisés pour inhiber l'activité de la protéine kinase |
CN113840842A (zh) | 2019-02-26 | 2021-12-24 | 詹森生物科技公司 | 利用双特异性抗EGFR/c-Met抗体的联合疗法和患者分层 |
CN114605400A (zh) * | 2019-03-19 | 2022-06-10 | 株式会社沃若诺伊 | 杂芳基衍生物、其制备方法、及含其作为有效成分的药物组合物 |
US20220175783A1 (en) | 2019-03-29 | 2022-06-09 | Astrazeneca Ab | Osimertinib for use in the treatment of non-small cell lung cancer |
CN111747950B (zh) * | 2019-03-29 | 2024-01-23 | 深圳福沃药业有限公司 | 用于治疗癌症的嘧啶衍生物 |
US11879013B2 (en) | 2019-05-14 | 2024-01-23 | Janssen Biotech, Inc. | Combination therapies with bispecific anti-EGFR/c-Met antibodies and third generation EGFR tyrosine kinase inhibitors |
US11850248B2 (en) * | 2019-05-14 | 2023-12-26 | Yuhan Corporation | Therapies with 3rd generation EGFR tyrosine kinase inhibitors |
CN110128354A (zh) * | 2019-06-20 | 2019-08-16 | 大连大学 | 一种5-氟-2-甲磺酰基-4-氨基嘧啶的制备方法 |
KR20210032093A (ko) | 2019-09-16 | 2021-03-24 | 제이투에이치바이오텍 (주) | Egfr 돌연변이 키나제 성장 억제 효과를 나타내는 피리미딘 유도체 및 이의 의약 용도 |
US20210161897A1 (en) | 2019-11-12 | 2021-06-03 | Astrazeneca Ab | Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer |
CA3166980A1 (fr) | 2020-01-20 | 2021-07-29 | Astrazeneca Ab | Inhibiteurs de tyrosine kinase du recepteur du facteur de croissance epidermique pour le traitement du cancer |
TW202207940A (zh) | 2020-04-14 | 2022-03-01 | 美商健生生物科技公司 | 包含胺基嘧啶衍生物或其醫藥上可接受之鹽、水合物、或溶劑化物之用於經口投予之醫藥組成物 |
US20210369709A1 (en) | 2020-05-27 | 2021-12-02 | Astrazeneca Ab | EGFR TKIs FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER |
KR20210152312A (ko) * | 2020-06-08 | 2021-12-15 | 주식회사 종근당 | 카나비노이드 수용체 (cb1 수용체) 길항제로서의 4-(4,5-디하이드로-1h-피라졸-1-닐)피리미딘 화합물 및 이를 포함하는 약제학적 조성물 |
CA3191538A1 (fr) | 2020-09-14 | 2022-03-17 | Ademi Elena SANTIAGO-WALKER | Therapies combinees d'inhibiteurs de fgfr |
TW202227425A (zh) * | 2020-09-18 | 2022-07-16 | 南韓商沃若諾伊生物公司 | 雜芳基衍生物、彼之製法、及包含彼作為活性成份之藥學組成物 |
WO2022131741A1 (fr) * | 2020-12-14 | 2022-06-23 | 보로노이바이오 주식회사 | Composé dérivé d'isoxazolidine et son utilisation |
WO2022234965A1 (fr) * | 2021-05-07 | 2022-11-10 | 주식회사 보로노이 | Dérivé hétéroaryle, son procédé de préparation et composition pharmaceutique le comprenant en tant que principe actif |
IL298474A (en) * | 2021-05-17 | 2023-01-01 | Voronoibio Inc | Compounds of heteroaryl derivatives and uses thereof |
CN117425651A (zh) | 2021-06-01 | 2024-01-19 | 杭州领业医药科技有限公司 | Lazertinib甲磺酸盐的水合物晶型及其制备方法和用途 |
KR20230054567A (ko) | 2021-10-15 | 2023-04-25 | 제이투에이치바이오텍 (주) | Alk 및/또는 egfr 돌연변이 키나제 억제 효과를 나타내는 화합물 및 이의 의약 용도 |
TW202342057A (zh) | 2022-02-07 | 2023-11-01 | 美商健生生物科技公司 | 用於減少用egfr/met雙特異性抗體治療之患者的輸注相關反應之方法 |
WO2023187037A1 (fr) | 2022-03-31 | 2023-10-05 | Astrazeneca Ab | Inhibiteurs de tyrosine kinase du récepteur du facteur de croissance épidermique (egfr) en combinaison avec un inhibiteur d'akt pour le traitement du cancer |
WO2023209086A1 (fr) | 2022-04-28 | 2023-11-02 | Astrazeneca Ab | Composés hétéroaromatiques bicycliques pour le traitement du cancer |
WO2023209084A1 (fr) | 2022-04-28 | 2023-11-02 | Astrazeneca Ab | Composés hétéroaromatiques bicycliques condensés et leur utilisation dans le traitement du cancer |
WO2023209088A1 (fr) | 2022-04-28 | 2023-11-02 | Astrazeneca Ab | Composés hétéroaromatiques bicycliques et leur utilisation dans le traitement du cancer |
WO2023209090A1 (fr) | 2022-04-28 | 2023-11-02 | Astrazeneca Ab | Composés hétéroaromatiques bicycliques et leur application dans le traitement du cancer |
WO2024002938A1 (fr) | 2022-06-27 | 2024-01-04 | Astrazeneca Ab | Combinaisons impliquant des inhibiteurs de tyrosine kinase du récepteur du facteur de croissance épidermique pour traiter le cancer |
WO2024008929A1 (fr) | 2022-07-08 | 2024-01-11 | Astrazeneca Ab | Inhibiteurs de tyrosine kinase du récepteur du facteur de croissance épidermique en combinaison avec des inhibiteurs du récepteur hgf pour le traitement du cancer |
WO2024096624A1 (fr) * | 2022-11-03 | 2024-05-10 | Voronoi Inc. | Sels de fumarate, tartrate, malate et de citrate d'un inhibiteur d'egfr |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030004174A9 (en) * | 2000-02-17 | 2003-01-02 | Armistead David M. | Kinase inhibitors |
CN1717396A (zh) * | 2002-11-28 | 2006-01-04 | 舍林股份公司 | Chk-、Pdk-和Akt-抑制嘧啶,其制备及作为药物的用途 |
JP4428565B2 (ja) | 2004-10-05 | 2010-03-10 | 東京エレクトロン株式会社 | 処理液塗布装置 |
US20070072894A1 (en) | 2005-03-24 | 2007-03-29 | Kempf J V | Synthesis of pyrroloquinoline quinone (PQQ) |
JP5007029B2 (ja) | 2005-07-13 | 2012-08-22 | Ntn株式会社 | グリース組成物および該グリース封入転がり軸受 |
AU2006283935A1 (en) | 2005-08-25 | 2007-03-01 | F. Hoffmann-La Roche Ag | Fused pyrazole as p38 MAP kinase inhibitors |
JP2007117465A (ja) | 2005-10-28 | 2007-05-17 | Sharp Corp | 集塵器およびそれを備えた電気掃除機 |
WO2007111471A1 (fr) | 2006-03-29 | 2007-10-04 | Ktfreetel Co., Ltd. | Dispositif numérique et procédé pour fournir un service complémentaire au moyen de ce dispositif |
EP2001480A4 (fr) | 2006-03-31 | 2011-06-15 | Abbott Lab | Composés d'indazole |
KR101955914B1 (ko) * | 2008-06-27 | 2019-03-11 | 셀젠 카르 엘엘씨 | 헤테로아릴 화합물 및 이의 용도 |
CN102482277B (zh) * | 2009-05-05 | 2017-09-19 | 达纳-法伯癌症研究所有限公司 | 表皮生长因子受体抑制剂及治疗障碍的方法 |
EA024729B1 (ru) | 2009-11-13 | 2016-10-31 | Джиноско | Киназные ингибиторы |
KR101671341B1 (ko) * | 2011-02-25 | 2016-11-01 | 주식회사유한양행 | 다이아미노피리미딘 유도체 및 그의 제조방법 |
ME02887B (fr) * | 2011-07-27 | 2018-04-20 | Astrazeneca Ab | Dérivés de 2-(2,4,5-substitué-anilino)pyrimidine utilisés comme modulateurs du récepteur egfr utiles pour le traitement du cancer |
JP6062962B2 (ja) * | 2012-01-20 | 2017-01-18 | ジェノスコ | 置換ピリミジン化合物およびsyk阻害剤としてのそれらの使用 |
WO2014040555A1 (fr) * | 2012-09-12 | 2014-03-20 | 山东亨利医药科技有限责任公司 | Dérivé de noyau hétéroaromatique contenant de l'azote utile comme inhibiteur de la tyrosine kinase |
US8957080B2 (en) * | 2013-04-09 | 2015-02-17 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
US10273224B2 (en) * | 2013-08-22 | 2019-04-30 | Jubilant Biosys Limited | Substituted pyrimidine compounds, compositions and medicinal applications thereof |
CN111875585B (zh) * | 2014-06-12 | 2023-06-23 | 上海艾力斯医药科技股份有限公司 | 一类激酶抑制剂 |
HUE048006T2 (hu) * | 2014-10-13 | 2020-05-28 | Yuhan Corp | Vegyületek és készítmények EGFR mutáns kináz aktivitás modulására |
CN104788427B (zh) * | 2015-02-05 | 2017-05-31 | 上海泓博智源医药股份有限公司 | 3‑(2‑嘧啶氨基)苯基丙烯酰胺类化合物及其应用 |
-
2015
- 2015-10-13 HU HUE15850314A patent/HUE048006T2/hu unknown
- 2015-10-13 LT LTEP19196713.2T patent/LT3604294T/lt unknown
- 2015-10-13 NZ NZ730012A patent/NZ730012A/en unknown
- 2015-10-13 DK DK15850314.4T patent/DK3207035T3/da active
- 2015-10-13 JP JP2017519685A patent/JP6524221B2/ja active Active
- 2015-10-13 PT PT158503144T patent/PT3207035T/pt unknown
- 2015-10-13 CA CA2962914A patent/CA2962914C/fr active Active
- 2015-10-13 RS RS20210608A patent/RS61865B1/sr unknown
- 2015-10-13 PL PL15850314T patent/PL3207035T3/pl unknown
- 2015-10-13 EP EP21171619.6A patent/EP3929190A1/fr active Pending
- 2015-10-13 CN CN201580055717.9A patent/CN106795144B/zh active Active
- 2015-10-13 KR KR1020177012969A patent/KR102073854B1/ko active Protection Beyond IP Right Term
- 2015-10-13 EP EP15850314.4A patent/EP3207035B1/fr active Active
- 2015-10-13 AU AU2015331166A patent/AU2015331166B2/en active Active
- 2015-10-13 HU HUE19196713A patent/HUE054848T2/hu unknown
- 2015-10-13 US US14/881,930 patent/US9593098B2/en active Active
- 2015-10-13 SI SI201531055T patent/SI3207035T1/sl unknown
- 2015-10-13 LT LTEP15850314.4T patent/LT3207035T/lt unknown
- 2015-10-13 CN CN202010422259.0A patent/CN111686110B/zh active Active
- 2015-10-13 MX MX2020002168A patent/MX2020002168A/es unknown
- 2015-10-13 TW TW108118264A patent/TWI730331B/zh active
- 2015-10-13 WO PCT/KR2015/010784 patent/WO2016060443A2/fr active Application Filing
- 2015-10-13 KR KR1020237000623A patent/KR102662358B1/ko active IP Right Grant
- 2015-10-13 SI SI201531611T patent/SI3604294T1/sl unknown
- 2015-10-13 KR KR1020207002949A patent/KR102208775B1/ko active IP Right Grant
- 2015-10-13 BR BR112017007769-8A patent/BR112017007769B1/pt active IP Right Grant
- 2015-10-13 ES ES15850314T patent/ES2770058T3/es active Active
- 2015-10-13 PT PT191967132T patent/PT3604294T/pt unknown
- 2015-10-13 RU RU2017116598A patent/RU2727700C2/ru active
- 2015-10-13 KR KR1020217002019A patent/KR102487451B1/ko active IP Right Grant
- 2015-10-13 ES ES19196713T patent/ES2879474T3/es active Active
- 2015-10-13 DK DK19196713.2T patent/DK3604294T3/da active
- 2015-10-13 SG SG11201701960XA patent/SG11201701960XA/en unknown
- 2015-10-13 RU RU2020123547A patent/RU2020123547A/ru unknown
- 2015-10-13 EP EP19196713.2A patent/EP3604294B1/fr active Active
- 2015-10-13 RS RS20200101A patent/RS59900B1/sr unknown
- 2015-10-13 MX MX2017003181A patent/MX2017003181A/es active IP Right Grant
- 2015-10-13 TW TW104133539A patent/TWI664173B/zh active
- 2015-10-13 KR KR1020247013986A patent/KR20240074820A/ko active Search and Examination
- 2015-10-13 PL PL19196713T patent/PL3604294T3/pl unknown
-
2017
- 2017-03-10 MX MX2021010761A patent/MX2021010761A/es unknown
- 2017-03-14 PH PH12017500488A patent/PH12017500488A1/en unknown
-
2019
- 2019-04-26 JP JP2019085608A patent/JP6754864B2/ja active Active
-
2020
- 2020-02-07 HR HRP20200201TT patent/HRP20200201T1/hr unknown
- 2020-02-17 CY CY20201100143T patent/CY1122737T1/el unknown
- 2020-08-24 JP JP2020141205A patent/JP2020196740A/ja not_active Withdrawn
-
2021
- 2021-06-14 HR HRP20210949TT patent/HRP20210949T1/hr unknown
- 2021-07-26 CY CY20211100670T patent/CY1124359T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20200201T1 (hr) | Spojevi i sastavi za moduliranje aktivnosti mutantne egfr kinaze | |
IL273058A (en) | Compositions and methods for modulation of PKK expression | |
HK1258811A1 (zh) | 用於調節cftr 的化合物、組合物和方法 | |
IL286669A (en) | Compounds and methods for modulating tmprss6 expression | |
HK1258275A1 (zh) | 用於調節血管緊張素原表達的化合物和方法 | |
IL246879B (en) | Preparations of Epilimod and methods of using them | |
ZA201700021B (en) | Alk kinase inhibitor, and preparation method and use thereof | |
HRP20180920T1 (hr) | Mješoviti travnjak | |
EP3102571A4 (fr) | Pyrimidines substituées utiles en tant qu'inhibiteurs de kinase d'egfr-t790m | |
PL3113774T3 (pl) | Kompozycje grapiprantu i sposoby ich zastosowania | |
IL252191B (en) | Compositions and methods for modulating at2r activity | |
SG10202003691PA (en) | Composition for modulating irak1 | |
GB201409661D0 (en) | Novel compounds and their use as kinase inhibitors | |
GB201405532D0 (en) | Novel compounds and their use as Kinase inhibitors |